Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other Events

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events.

On November 15, 2016, Aclaris Therapeutics, Inc. (the Company)
issued a press release announcing top-line results from its Phase
3 clinical trial of A-101 for the treatment of seborrheic
keratosis, as well as information regarding a conference call to
discuss these results. The full text of the Companys press
release is filed as Exhibit99.1 to this Current Report on Form8-K
and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit

Number

ExhibitDescription

99.1

Press Release, dated November 15, 2016, titled Aclaris
Therapeutics Announces Positive Top-Line Phase 3 Results
for A-101 In Treating Seborrheic Keratosis, a Common
Undertreated Skin Condition


About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)


An ad to help with our costs